Patient characteristics (N = 96)
| Characteristic . | % . | Median (range) . |
|---|---|---|
| Baseline characteristics before CAR T-cell transfusion | ||
| Age, y | 58 (20-83) | |
| Female sex | 30.2 | |
| Diagnosis | ||
| DLBCL | 68.8 | |
| BCP-ALL | 12.5 | |
| Other lymphoma/leukemia subtypes* | 18.7 | |
| ECOG PS | ||
| 0 | 53.1 | |
| 1 | 44.8 | |
| 2 | 2.1 | |
| 3 | 0 | |
| 4 | 0 | |
| 5 | 0 | |
| NfL, pg/mL | 31.8 (1.8-436.0) | |
| Administered CAR T-cell product | ||
| Axicabtagene ciloleucel | 51.0 | |
| Tisagenlecleucel | 22.9 | |
| Other products† | 26.0 | |
| Outcome parameters after CAR T-cell transfusion | ||
| ECOG PS | ||
| 0 | 45.7 | |
| 1 | 31.9 | |
| 2 | 28.3 | |
| 3 | 3.2 | |
| 4 | 1.1 | |
| 5 | 12.8 | |
| CRS grade | ||
| 0 | 29.2 | |
| 1 | 42.7 | |
| 2 | 22.9 | |
| 3 | 5.2 | |
| 4 | 0 | |
| ICANS grade | ||
| 0 | 63.5 | |
| 1 | 13.5 | |
| 2 | 10.4 | |
| 3 | 7.3 | |
| 4 | 5.2 | |
| NfL (pg/mL) | 31.1 (15.9-867.0) | |
| Outcome after 3 mo | ||
| CR | 25.6 | |
| PR | 18.3 | |
| SD | 12.2 | |
| MR | 2.4 | |
| PD | 41.5 | |
| Characteristic . | % . | Median (range) . |
|---|---|---|
| Baseline characteristics before CAR T-cell transfusion | ||
| Age, y | 58 (20-83) | |
| Female sex | 30.2 | |
| Diagnosis | ||
| DLBCL | 68.8 | |
| BCP-ALL | 12.5 | |
| Other lymphoma/leukemia subtypes* | 18.7 | |
| ECOG PS | ||
| 0 | 53.1 | |
| 1 | 44.8 | |
| 2 | 2.1 | |
| 3 | 0 | |
| 4 | 0 | |
| 5 | 0 | |
| NfL, pg/mL | 31.8 (1.8-436.0) | |
| Administered CAR T-cell product | ||
| Axicabtagene ciloleucel | 51.0 | |
| Tisagenlecleucel | 22.9 | |
| Other products† | 26.0 | |
| Outcome parameters after CAR T-cell transfusion | ||
| ECOG PS | ||
| 0 | 45.7 | |
| 1 | 31.9 | |
| 2 | 28.3 | |
| 3 | 3.2 | |
| 4 | 1.1 | |
| 5 | 12.8 | |
| CRS grade | ||
| 0 | 29.2 | |
| 1 | 42.7 | |
| 2 | 22.9 | |
| 3 | 5.2 | |
| 4 | 0 | |
| ICANS grade | ||
| 0 | 63.5 | |
| 1 | 13.5 | |
| 2 | 10.4 | |
| 3 | 7.3 | |
| 4 | 5.2 | |
| NfL (pg/mL) | 31.1 (15.9-867.0) | |
| Outcome after 3 mo | ||
| CR | 25.6 | |
| PR | 18.3 | |
| SD | 12.2 | |
| MR | 2.4 | |
| PD | 41.5 | |
CR, complete remission; ECOG, Eastern Cooperative Oncology Group; PR, partial remission; SD, stable disease; MR, mixed response; PD, progressive disease.
Follicular lymphoma, primary mediastinal B-cell lymphoma, mantle cell lymphoma, high-grade B-cell lymphoma, chronic lymphatic leukemia, mixed-phenotype acute leukemia.
Brexucabtagen autoleucel (n = 1) and an investigational third-generation CD19-targeted CAR T-cell product9 (n = 24).